Dr. Ρούσσου Mαρία MD, MSc, PhD

Σπουδές

• Διδάκτωρ, Ιατρική Σχολή, Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών (2004 - 2009)
• Μεταπτυχιακό στον "Σακχαρώδη Διαβήτη και Παχυσαρκία", Ιατρική Σχολή, Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών (2016 - 2018)
• Μεταπτυχιακό στην "Κλινική Ιατρική, Εργαστηριακή Ιατρική, Προληπτική και Κοινωνική Ιατρική", Ιατρική Σχολή, Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών (2005 - 2007)
• Πτυχίο Ιατρικής, Ιατρική Σχολή, Εθνικό & Καποδιστριακό Πανεπιστήμιο Αθηνών (1993 - 1999)
• Ειδικότητα Παθολογίας, Γενικό Νοσοκομείο Αθηνών «Αλεξάνδρα» (2003 - 2008)

Επαγγελματική εμπειρία

• Ιδιωτικό ιατρείο, Χαλάνδρι (2009 - σήμερα)
• Επιστημονική Συνεργάτις, Θεραπευτική Κλινική Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών, Γενικό Νοσοκομείο Αθηνών "Αλεξάνδρα"
• Ακαδημαϊκή Υπότροφος, Θεραπευτική Κλινική Εθνικού και Καποδιστριακού Πανεπιστημίου Αθηνών, Γενικό Νοσοκομείο Αθηνών "Αλεξάνδρα"
• Υπηρεσία υπαίθρου, Γενικό Νοσοκομείο Χαλκίδας & Κέντρο Υγείας Ιστιαίας (1999 - 2001)

Δημοσιεύσεις

• Theodorakakou F, Fotiou D, Spiliopoulou V, Roussou M, Malandrakis P, Ntanasis-Stathopoulos I, Migkou M, Eleutherakis-Papaiakovou E, Kanellias N, Papanikolaou A, Gavriatopoulou M, Terpos E, Dimopoulos MA, Kastritis E. Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy. Br J Haematol. 2023 Nov;203(3):411-415. doi: 10.1111/bjh.19042. Epub 2023 Aug 14. PMID: 37580907. (2023)
• Gavriatopoulou M, Kastritis E, Kyrtsonis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, Dimopoulos MA. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leuk Lymphoma. 2017 Jun;58(6):1506-1508. doi: 10.1080/10428194.2016.1233541. Epub 2016 Oct 10. PMID: 27724158. (2017)
• Terpos E, Christoulas D, Kastritis E, Bagratuni T, Gavriatopoulou M, Roussou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Liakou C, Panagiotidis I, Migkou M, Kokkoris P, Moulopoulos LA, Dimopoulos MA. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. Blood Cancer J. 2016 Oct 7;6(10):e482. doi: 10.1038/bcj.2016.90. PMID: 27716740; PMCID: PMC5098262. (2016)
• Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M, Komitopoulou A, Skevaki C, Eleutherakis-Papaiakovou E, Pamboucas C, Psimenou E, Manios E, Giannouli S, Politou M, Gakiopoulou H, Papadopoulou E, Stamatelopoulos K, Tasidou A, Dimopoulos MA. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016 Jul 21;128(3):405-9. doi: 10.1182/blood-2016-02-702696. Epub 2016 May 10. PMID: 27166361. (2016)
• Zagouri F, Roussou M, Kastritis E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kalapanida D, Christoulas D, Migkou M, Terpos E, Dimopoulos MA. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. Leuk Lymphoma. 2016 Aug;57(8):1776-80. doi: 10.3109/10428194.2016.1151513. Epub 2016 Feb 25. PMID: 26916452. (2016)
• Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia. 2014 Apr;28(4):928-34. doi: 10.1038/leu.2013.267. Epub 2013 Sep 18. PMID: 24045498. (2014)
• Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E, Dimopoulos MA. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol. 2013 Sep;88(9):765-70. doi: 10.1002/ajh.23504. Epub 2013 Jul 24. PMID: 23757261. (2013)
• Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6. PMID: 23183429. (2013)
• Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5. PMID: 22763386. (2013)
• Terpos E, Tasidou A, Eleftherakis-Papaiakovou E, Christoulas D, Gavriatopoulou M, Gkotzamanidou M, Roussou M, Kastritis E, Papadaki T, Dimopoulos MA. Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):115-7. doi: 10.3816/CLML.2011.n.024. PMID: 21454208. (2011)
• Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA. Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. Eur J Haematol. 2011 Oct;87(4):323-9. doi: 10.1111/j.1600-0609.2011.01659.x. Epub 2011 Aug 26. PMID: 21631590. (2011)
• Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, Dimopoulos MA, Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010 Nov;85(11):863-7. doi: 10.1002/ajh.21855. PMID: 20882526. (2010)
• Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26. PMID: 20739955. (2010)
• Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther. 2009 Apr;9(4):465-79. doi: 10.1517/14712590902845610. Erratum in: Expert Opin Biol Ther. 2009 May;9(5):675. PMID: 19344283. (2009)
• Dimopoulos MA, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Rituximab-based treatments in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar;9(1):59-61. doi: 10.3816/CLM.2009.n.015. PMID: 19362975. (2009)
• Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009 Jun;23(6):1152-7. doi: 10.1038/leu.2008.402. Epub 2009 Feb 19. PMID: 19225533. (2009)
• Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009 Nov;23(11):2177-81. doi: 10.1038/leu.2009.130. Epub 2009 Jul 9. PMID: 19587705. (2009)
• Roussou M, Anagnostopoulos A, Kastritis E, Matsouka C, Barmparousi D, Koutsoukou V, Dimopoulos MA. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments. Leuk Lymphoma. 2007 Apr;48(4):754-8. doi: 10.1080/10428190601186168. PMID: 17454634. (2007)
• Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007 Apr;92(4):546-9. doi: 10.3324/haematol.10759. PMID: 17488666. (2007)
• Zotos PG, Psimenou E, Roussou M, Kontogiannis S, Panoutsopoulos A, Dimopoulos AM. Nephrotic syndrome as a manifestation of Toxocara canis infection. Nephrol Dial Transplant. 2006 Sep;21(9):2675-6. doi: 10.1093/ndt/gfl224. Epub 2006 Jun 9. PMID: 16766549. (2006)
• περισσότερα